文献速递肝病

代谢功能障碍相关脂肪性肝病相关肝纤维化的最佳人群筛查策略

Optimal Population Screening Strategies for Liver Fibrosis Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease.
PubMed 文献 · Am J Gastroenterol · 2025-01-03

该研究基于2017-20年美国国家健康与营养调查数据,比较现行指南(FIB-4初筛)与基于SAFE评分的新人群筛查策略在MASLD肝纤维化检出中的效果。新策略可多检出37%的LSM≥8 kPa者和45%的LSM≥12 kPa者,同时减少28%的VCTE检查量。

要点

  • 基于SAFE评分的人群风险分层策略较现行指南更简单且更有效。
  • 新策略检出LSM≥8 kPa者4.9百万例,较指南3.5百万例提高37%。
  • 新策略检出LSM≥12 kPa者2.5百万例,较指南1.7百万例提高45%。

核心结论

  • 基于SAFE评分的人群风险分层策略更简单且更有效,较现行推荐算法可检出更多肝纤维化患者且所需资源更少。

研究设计与样本

  • 基于2017-20年美国国家健康与营养调查数据,对具有美国平民代表性的接受振动控制瞬时弹性成像(VCTE)的样本进行分析。
  • 将现行指南与基于SAFE评分的新提案应用于该数据,推算肝纤维化诊断人数及所需VCTE检查次数。

关键数值与推荐

  • 显著纤维化定义为LSM≥8 kPa,进展期纤维化定义为LSM≥12 kPa。
  • 现行指南推荐使用FIB-4评分进行风险人群初筛。
  • SAFE评分近期被开发用于初级保健中的MASLD风险分层。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important public health threat, potentially leading to chronic liver disease and liver cancer. Current guidelines recommend using the Fibrosis-4 score for initial identification of subjects at risk of future complications. We formulate a novel population screening strategy based on the Steatosis-Associated Fibrosis Estimator (SAFE) score, recently developed for MASLD risk stratification in primary care. METHODS: We interrogated the National Health and Nutrition Examination Survey data, 2017-20, in which a sample of subjects representative of US civilian population underwent vibration-controlled transient elastography (VCTE). The current guideline and a new, SAFE-based proposal were applied to these data to project the number of subjects to be diagnosed with liver fibrosis gauged by liver stiffness measurement (LSM), including significant (LSM ≥8 kPa) and advanced (LSM ≥12 kPa) fibrosis, as well as the number of VCTEs to be performed. RESULTS: In the survey data, 2,691 subjects, projecting to 75.8 million US adults, were found to have MASLD, of whom 11% had LSM 8-12 kPa and 6% LSM ≥12 kPa. When the current guideline was applied, 18.1 million VCTEs would be needed to diagnose 3.5 million subjects with LSM ≥8 kPa and 1.7 million subjects with LSM ≥12 kPa. In comparison, a new approach based on the SAFE score would detect 4.9 million with LSM ≥8 kPa and 2.5 million subjects with LSM ≥12 kPa (37% and 45% improvement over the current guideline, respectively), while requiring 5.0 million fewer VCTEs (28% reduction). DISCUSSION: The proposed population risk stratification approach using the SAFE score is simpler and substantially more effective, yielding more subjects with liver fibrosis while requiring less resources compared with the currently recommended algorithm.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Kim WR, Mannalithara A, Charu V, et al. Optimal Population Screening Strategies for Liver Fibrosis Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease. Am J Gastroenterol. 2025. PMID: 39749918. doi:10.14309/ajg.0000000000003268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。